| abstract |
The invention provides an application of an ANXA6 expression inhibitor in preparing a medicine for treating lung cancer. The present invention finds that: after ANXA6 expression is inhibited, the proliferation of lung cancer cells is significantly inhibited, the colony formation ability of lung cancer cells is inhibited, the subcutaneous tumorigenic ability of lung cancer cells is significantly decreased, and the growth rate of tumors is significantly inhibited. The invention also provides a medicine for treating lung cancer, which utilizes the CRISPR gene editing principle to knock out the ANXA6 gene in lung cancer cells, thereby having a therapeutic effect on lung cancer. |